Actinium Announces Encouraging Preclinical Data Of ATNM-400 For Prostate Cancer Treatment, Stock Up

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), Monday announced preclinical results of ATNM-400, a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 radioisotope for prostate cancer.

The data, presented at the American Association for Cancer Research Annual Meeting, showed that ATNM-400 outperforms Pluvicto, a prostate-specific membrane antigen.

The findings highlighted ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working.

Additionally, ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8 percent tumor growth inhibition achieved.

Currently, Actinium's stock is trading at $1.36, up 3.69 percent on the New York Stock Exchange American.